Market Research Reports and Industry Reports

Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

VPGMarketResearch’s new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

Worldwide Market Overview

- Five-year test volume and sales projections by country.

- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.

- Estimated universe of laboratories performing cancer diagnostic testing by country.

- Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others.

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers by individual test and country.

- Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:

- Hospitals - Commercial/Private Laboratories - Physician Offices/Group Practices - Cancer Clinics - Ambulatory Care Centers

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

   - Abbott    - AdnaGen    - Agilent Technologies    - Applied Gene Technologies    - Arca Biopharma    - Beckman Coulter/Danaher    - Becton Dickinson    - Biomedical Diagnostics    - bioMerieux    - Bio-Rad    - CellSearch    - Cepheid    - Correlogic Systems/Vermillion    - Decode Genetics    - Diadexus    - Diagnocure    - DiaSorin    - Eiken Chemical    - Elitech Group    - Enterix    - Enzo Biochem    - Epigenomics    - Fujirebio    - Guided Therapeutics    - Hologic/Gen-Probe    - Kreatech/Leica    - Kyowa Medex    - Mackay Life Sciences    - Myriad Genetics    - OncoLab    - Ortho-Clinical Diagnostics    - Panacea Pharmaceuticals    - Polartechnics    - Polymedco    - PreMD    - Qiagen    - Quest Diagnostics    - Radient Pharmaceuticals    - Roche    - Scienion    - Sequenom    - Siemens Healthcare    - Takara Bio    - Targeted Diagnostics & Therapeutics    - Thermo Fisher    - Tosoh    - Veridex    - Wako Pure Chemicals    - Wallac/PE    - Zilla

Contains 1,200 pages and 450 tables



I. Introduction

II. Worldwide Market Overview
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth

III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. Design Criteria for Decentralized Testing Products

V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor

VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
Table of Contents
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin


List Of Tables

    

Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
List of Tables
Major Companies Developing or Marketing
HCG Tests
Major Companies Developing or Marketing
Insulin Tests
Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
List of Tables
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: France, Total Cancer
Diagnostic Test Volume and Sales Forecast
by Market Segment
France, Estimated Cancer Death Rates
Per 100,000 Population
France, Laboratories Performing Tumor
Marker Tests by Market Segment
France, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
France, Commercial/Private Laboratories
Performing Tumor Markers by Annual Test Volume
France, Total Tumor Marker Test Volume
Forecast by Market Segment
France, All Market Segments Major Tumor
Marker Test Volume Forecast
France, Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
France, Commercial/Private Laboratories
Marker Test Volume Forecast
France, Total Tumor Marker Sales Major Tumor
Forecast by Market Segment
France, All Market Segments Major Tumor
Marker Sales Forecast by Test
France, Hospital Laboratories Major Tumor
Marker Sales Forecast by Test


Global Penile Cancer Treatment Market Research Report 2016

2016 Global Penile Cancer Treatment Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Penile Cancer Treatment industry, focusing on the

USD 2850View Report

Global Blood Cancer Market Research Report 2016

2016 Global Blood Cancer Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Blood Cancer industry, focusing on the main regions

USD 2850View Report

Global Kinase Inhibitors For Cancer Treatment Market Research Report 2016

2016 Global Kinase Inhibitors For Cancer Treatment Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Kinase Inhibitors For Cancer Treatment

USD 2850View Report

Clinical Chemistry and Immunodiagnostics: A Market in Transition amid Regulatory Uncertainty and Intensifying Competition--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

Complete report $24,500.  DataPack (test volumes, sales forecasts, supplier shares) $15,900.VPGMarketResearch’s new seven-country report is a strategic analysis of major business opportunities emerging in the global clinical chemistry and immunodiagnostic

USD 24500View Report

2016-2020 CompetitiveWatch Cancer Diagnostics: Major Suppliers Strategic Assessments

This report presents strategic analyses of major current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products

USD 2500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF    $ 24500
  • Global Licence    $ 53900
  • DataPack    $ 15900
$ 24500

Reports Details

Published Date : Aug 2016
No. of Pages :1200
Country :Global
Category :Healthcare
Publisher :VPGMarketResearch.com
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment